Tech Company Financing Transactions
Quanta Therapeutics Funding Round
On 5/22/2023, Quanta Therapeutics raised $50.7 million in Series D investment from Avidity Partners, AbbVie Biotech Ventures and BVF Partners.
Transaction Overview
Company Name
Announced On
5/22/2023
Transaction Type
Venture Equity
Amount
$50,700,000
Round
Series D
Investors
Proceeds Purpose
The proceeds from the financing will be used to advance Quanta's pipeline including: Two chemically distinct allosteric KRAS inhibitors, QTX3034, a multi-KRAS inhibitor, and QTX3046, a G12D-selective KRAS inhibitor. Data from both programs, recently presented at the American Association for Cancer Research (AACR) Annual Meeting, demonstrated favorable preclinical profiles, including potent anti-tumor activity with oral bioavailability and brain penetration. These programs are currently in Investigational New Drug Application (IND)-enabling studies to support anticipated clinical trial initiation in KRAS-driven solid tumor indications in 2024.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Two Tower Place, 14th Floor South
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Novel therapeutics for conformational blockade of RAS in cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Perry Nisen
Chief Medical Officer
Leonardo Faoro
Co-Founder
Cameron Pitt
Browse more venture capital transactions:
Prev: 5/22/2023: Volition venture capital transaction
Next: 5/22/2023: Onyx Private venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs